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E
ndogenous erythropoietin production
becomes inadequate in most recipients of
allogeneic bone marrow transplantation
(BMT) 2-3 weeks after transplant.1
Administration of rHuEpo to these patients
can accelerate erythroid recovery and reduce
red cell transfusion requirements, not only with
no stem-cell competition but with a beneficial
effect on platelet recovery.2
Long-lasting anemia is frequently observed
following autologous BMT (using either bone
marrow or peripheral stem cells). In this set-
ting, however, endogenous erythropoietin pro-
duction in generally adequate and the develop-
ment of erythropoiesis is mainly determined by
marrow proliferative capacity.3 Due to this and
to the scarcity of committed progenitors
infused, administration of rHuEpo is usually
not effective in stimulating erythroid repopula-
tion after autologous BMT.4
In this report, we describe a patient who
developed pure red cell aplasia (PRCA) follow-
ing peripheral stem cell transplantation. In
spite of appropriate endogenous erythropoietin
production, he responded to pharmacological
doses of recombinant human erythropoietin
with complete correction of anemia.
Case report
A 48-year-old man was first seen at the
Department of Hematology, Rome, in 1988 for
a non-Hodgkin lymphoma (follicular, predom-
inantly large cell; D according to the Working
Formulation). There was bone marrow infiltra-
tion, indicating a clinical stage IV. Treatment
with F-MACHOP produced a partial remission
but mild bone marrow involvement persisted;
since the patient was asymptomatic, it was
decided to follow him without further therapy.
In September, 1990, lymph node enlargement
reappeared. The patient was treated with an
alternative drug combination (PROVECIP:
procarbazine, vinblastine, cyclophosphamide,
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We studied a patient who developed pure red cell aplasia (PRCA) following peripheral stem cell
transplantation for non-Hodgkin lymphoma. Serum erythropoietin was appropriate for the
degree of anemia. Corticosteroid treatment was ineffective. Four months after transplantation
rHuEpo was administered subcutaneously at a dose of 150 U/Kg per day, five days a week for 8
weeks. Treatment induced an erythropoietic response and corrected anemia. Response was main-
tained following discontinuation of rHuEpo. This study and previous reports indicate that high
doses of rHuEpo given over a short time can resolve PRCA following autologous or allogeneic
stem cell transplantation.
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prednisone) and achieved complete remission
after four cycles. Remission was maintained
with 12 additional cycles.
In 1992, at the end of this maintenance thera-
py, the patient agreed to undergo high-dose
chemotherapy with peripheral stem cell trans-
plantation. Peripheral stem cells were mobilized
with high-dose cyclophosphamide followed by
G-CSF, and the BEAC protocol was adopted as
conditioning regimen. Transplantation was per-
formed in July 1992.
Hemopoietic recovery was delayed; in partic-
ular, the patient showed a high transfusion
requirement in order to maintain a hemoglobin
level around 8 g/dL (Figure 1). Two months
after transplantation, bone marrow biopsy
showed a hypoplastic marrow with an almost
total absence of erythroid precursors, a picture
indicating PRCA. Corticosteroid treatment was
ineffective and reticulocyte count remained
fixed at zero.
Serum erythropoietin was 420 mU/mL and
the observed/predicted log(erythropoietin)
ratio (O/P ratio) was 1.11 (the O/P ratio aver-
ages 1.00±0.11 in reference subjects, 95% confi-
dence interval: 0.80-1.22). The value found in
our patient indicated normal endogenous ery-
thropoietin production.5
Despite this, we decided to administer
rHuEpo on a compassionate basis. rHuEpo was
kindly provided by Boehringer Mannheim
Italia, Monza, Italy, and was administered sub-
cutaneously daily at a dose of 150 units per
kilogram of body weight, five days a week.
Response to treatment was initially suggested
by steady increases in serum transferrin receptor
(TfR) and reticulocyte count. Available evidence
indicates that serum transferrin receptor is a
truncated form of surface receptors, that its
major source is the erythroid precursors in the
bone marrow and that its serum level is a mea-
sure of erythroid marrow activity.6 Normal TfR
levels average 5.0±1.1 mg/L and 95% confidence
limits range from 2.9 to 7.1 mg/L. Serum TfR
concentration ranged from 0.4 to 0.8 mg/L in
our patient before beginning rHuEpo, values
typically found in aplastic anemia. TfR level nor-
malized after four weeks of treatment (Figure 1).
Corrected reticulocyte count increased from 0 to
4.3 % by week 5; rHuEpo treatment was discon-
tinued after 8 weeks and Hb remained stable in a
range of 13.5 to 15 g/dL. The serum erythropoi-
etin level was 29 mU/mL post-therapy, with a
Hb of 14.9 g/dL. Erythropoietic response to
rHuEpo was also typical in terms of body iron
status parameters. In fact, serum ferritin fell
from 2106 to 169 e/L, and serum iron from 237
to 37 eg/dL (Figure 1).
Discussion
Following autologous BMT our patient devel-
oped PRCA while maintaining normal endoge-
nous erythropoietin production. In spite of
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Figure 1. Clinical course of our patient. rHuEpo was started
at time 0. T indicates peripheral stem cell transplantation.
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this, he responded to high doses of rHuEpo
with complete correction of anemia. Other
reports have also described the positive effects
of rHuEpo in PRCA (Table 1).
Heyll et al.7 treated a patient with PRCA after
major ABO-incompatible bone marrow trans-
plantation. Serum erythropoietin was markedly
increased (560 mU/mL): treatment with
rHuEpo induced reticulocytosis and corrected
the anemia. Similar cases were later reported by
Paltiel et al.8 and Taniguchi et al.9 It is notewor-
thy that two of these three cases did not
respond to standard doses of rHuEpo (about 75
U/kg 3 times a week). Escalation from alter-
nate-day to daily administration resolved
PRCA.
Responses to rHuEpo in PRCA patients have
also been observed outside the transplantation
setting. Finelli et al.10 reported a patient with
idiopathic PRCA who did not respond to corti-
costeroids. Subsequent treatment with rHuEpo
was effective in ameliorating anemia. Zeigler et
al.11 studied a patient with PRCA associated with
myeloid metaplasia who failed to respond to
immunological agents. Her serum erythropoi-
etin level was 907 mU/mL with a Hb of 7.9
g/dL. rHuEpo was administered at 500 U/Kg
intravenously three times a week. Hemoglobin
increased from 7.9 to 12 g/dL after 2 months.
When the patient declined further therapy, she
suffered a relapse of her red cell aplasia. Overall,
all these responsive patients with idiopathic
PRCA relapsed after discontinuation of rHuEpo.
Although PRCA is frequently observed fol-
lowing ABO-incompatible allogeneic BMT, the
mechanism behind this is still not clear.8 All but
one case reported involved blood group O
recipients of bone marrow from blood group A
M. Martelli et al.
Authors Condition and endogenous
erythropoietin production
Treatment and outcome
Heyll et al (7) PRCA after major ABO-incompatible
allogeneic BMT lasting > 230 days.
Serum epo was markedly increased (560
mU/mL)
rHuEpo at a dose of 4,000 U sc three times weekly
was ineffective. The dose was increased to 4,000 U
daily and an erythropoietic response was soon
observed: reticulocytes appeared within one week.
Complete correction of anemia was achieved in 3-4
weeks and was maintained after discontinuation of
rHuEPO.
Paltiel et al (8) PRCA after major ABO-incompatible
allogeneic BMT lasting > 230 days.
Serum epo was increased (360 mU/mL).
Erythroid engraftment was observed soon after
the initiation of rHuEpo at a dose of 50 U/kg daily.
Complete correction of anemia was achieved in 3
weeks and was maintained after discontinuation of
rHuEPO.
Taniguchi et al (9) PRCA after major ABO-incompatible
allogeneic BMT lasting > 200 days.
Serum epo was markedly increased (720
mU/mL).
rHuEpo at a dose of 4,500 U sc daily was
   ineffective. The dose was increased to 9,000 U
daily and an erythropoietic response was soon
observed. Complete correction of anemia was
achieved in 3  weeks and was maintained after
discontinuation of rHuEPO.
Present report PRCA after peripheral stem cell
transplantation lasting 120 days. Serum
epo was markedly increased (420
mU/mL).
Erythroid engraftment was observed soon after
the initiation of rHuEpo at a dose of 10,000 U sc
daily, 5 days weekly. Complete correction of anemia
was achieved in 8 weeks and was maintained after
discontinuation of rHuEPO.
Table 1. Case reports on the use of rHuEpo in the treatment of pure red cell aplasia after stem cell transplantation.
rHuEpo in PRCA following stem cell transplantation 459
donors. It has been proposed that circulating
isoagglutinins may inhibit erythroid progenitor
proliferation in these patients. High doses of
rHuEpo would overcome such inhibition and
allow erythroid precursor proliferation; this, in
turn, would neutralize the circulating inhibitors
and result in effective red cell production.8
Our patient was autotransplanted with auto-
logous peripheral stem cells so that no ABO-
incompatibility was involved in the pathogene-
sis of his PRCA. A working hypothesis is that
excessive apoptosis of erythroid progenitors
may occur in some patients following BMT.3
This prevents erythroid engraftment since most
CFU-Es die and few or no erythroblasts are
formed. Erythropoietin has been demonstrated
to be a survival factor for erythroid cells that
expands erythropoiesis by preventing the apop-
tosis of erythroid progenitors and proerythro-
blasts.12
Thus, administration of rHuEpo may over-
come the excessive death of erythroid progeni-
tors in PRCA and allow sufficient production of
erythroid precursors and erythroid engraft-
ment.
A word of caution, however, must be spent
about the interpretation of serum erythropoi-
etin levels in PRCA. A relationship does exist
between red cell precursor mass and erythropoi-
etin clearance.5 The latter must be somewhat
slower in patients with PRCA, who completely
lack erythroid precursors; in this case, the
observed serum levels would overestimate
endogenous erythropoietin production. 
Therefore the possibility exists that the bene-
ficial effects of rHuEpo reflect a condition of
inadequate endogenous erythropoietin produc-
tion in spite of high serum levels.
From a practical point of view, the present
study and previous reports suggest that any
patient with PRCA unresponsive to conven-
tional therapy, especially following BMT,
deserves treatment with a short course of high-
dose rHuEpo.
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